Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Systematic Reviews
Published in: Systematic Reviews 1/2017

Open Access 01-12-2017 | Protocol

The association between adverse pregnancy outcomes and maternal human papillomavirus infection: a systematic review protocol

Authors: Joseph Niyibizi, Nadège Zanré, Marie-Hélène Mayrand, Helen Trottier

Published in: Systematic Reviews | Issue 1/2017

Login to get access

Abstract

Background

Human papillomavirus (HPV) is the most prevalent genital infection, especially in young women of reproductive age. In vitro and animal model experiments provide compelling evidence of the harmful effect of HPV on pregnancy outcomes, but results from epidemiologic studies are inconclusive. We aim to determine the strength of the relationship between adverse pregnancy outcomes (APO) and HPV infection and assess its consistency across studies, by systematically reviewing the literature.

Methods

The search strategy has been developed on the basis of the PICOS framework: Population (pregnant women); Exposure (HVP infection confirmed by HPV testing); Comparator (pregnant women without HPV infection); Outcomes (miscarriage, spontaneous preterm birth, low birth weight, preterm premature rupture of membranes, pregnancy-induced hypertensive disorders and intrauterine growth restriction) and Study design (observational studies). We will search three information sources: (1) electronic databases (MEDLINE, EMBASE, and EBM Reviews databases); (2) Grey literature (Google Scholar and Web of Science conference proceedings); and (3) citing and cited articles of included studies. Two reviewers (JN, NZ) will independently and in duplicate screen identified articles, select eligible studies, and extract data. Discrepancies will be resolved by consensus and otherwise by discussion with the other authors (MHM, HT). Quality of included studies will be assessed using the Effective Public Health Practice Project (EPHPP) Quality Assessment Tool for Quantitative Studies. We will narratively synthesize extracted data whether meta-analysis is conducted or not. Meta-analysis of each outcome will be performed, and where appropriate, an average measure of association will be computed. We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess and grade the strength of confidence in cumulative estimate.

Discussion

Comprehensive and high-quality evidence of a negative effect of HPV on pregnancy outcomes might be an additional motivation for HPV vaccination. Absence of such relationship could dispel anxiety and reassure HPV-infected pregnant women and clinicians. Findings of a poor level of confidence will allow identification of current knowledge gaps on HPV-pregnancy outcome relationship that need further research.

Systematic review registration

PROSPERO CRD42016033425
Appendix
Available only for authorised users
Literature
1.
Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, Su J, Xu F, Weinstock H. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis. 2013;40(3):187–93.CrossRefPubMed
2.
Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4.CrossRefPubMed
3.
Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26 Suppl 10:K1–16.
4.
Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 2009;12(5-6):291–307.CrossRefPubMed
5.
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.CrossRefPubMed
6.
Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JC, Rohan TE, Villa LL, Franco EL. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010;70(21):8569–77.CrossRefPubMedPubMedCentral
7.
Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health. 2011;48(6):540–52.CrossRefPubMed
8.
Rachel Skinner S, Wheeler CM, Romanowski B, Castellsague X, Lazcano-Ponce E, Rowena Del Rosario-Raymundo M, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138(10):2428–38.CrossRefPubMedPubMedCentral
9.
Liu P, Xu L, Sun Y, Wang Z. The prevalence and risk of human papillomavirus infection in pregnant women. Epidemiol Infect. 2014;142(8):1567–78.CrossRefPubMed
10.
Jalil EM, Bastos FI, Melli PPS, Duarte G, Simoes RT, Yamamoto AY, Morais RAA, Quintana SM. HPV clearance in postpartum period of HIV-positive and negative women: a prospective follow-up study. BMC Infect Dis. 2013;13:564.CrossRefPubMedPubMedCentral
11.
Nobbenhuis MAE, Helmerhorst TJM, van den Brule AJC, Rozendaal L, Bezemer PD, Voorhorst FJ, Meijer CJLM. High-risk human papillomavirus clearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum. Br J Cancer. 2002;87(1):75–80.CrossRefPubMedPubMedCentral
12.
Fife KH, Katz BP, Brizendine EJ, Brown DR. Cervical human papillomavirus deoxyribonucleic acid persists throughout pregnancy and decreases in the postpartum period. Am J Obstet Gynecol. 1999;180(5):1110–4.CrossRefPubMed
13.
Castellsague X, Drudis T, Canadas MP, Gonce A, Ros R, Perez JM, Quintana MJ, Munoz J, Albero G, de Sanjose S, et al. Human papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. BMC Infect Dis. 2009;9:74.CrossRefPubMedPubMedCentral
14.
Druckmann R, Druckmann MA. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol. 2005;97(5):389–96.CrossRefPubMed
15.
Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, Chaiworapongsa T, Mazor M. The preterm parturition syndrome. Bjog. 2006;113 Suppl 3:17–42.CrossRefPubMed
16.
Donati L, Di Vico A, Nucci M, Quagliozzi L, Spagnuolo T, Labianca A, Bracaglia M, Ianniello F, Caruso A, Paradisi G. Vaginal microbial flora and outcome of pregnancy. Arch Gynecol Obstet. 2010;281(4):589–600.CrossRefPubMed
17.
Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SE, Horne AW. The role of infection in miscarriage. Hum Reprod Update. 2016;22(1):116–33.CrossRefPubMed
18.
Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Varner MW, Andrews W, Saade G, Sadovsky Y, et al. The phenotype of spontaneous preterm birth: application of a clinical phenotyping tool. Am J Obstet Gynecol. 2015;212(4): 487.e1-487.e11.
19.
Rustveld LO, Kelsey SF, Sharma R. Association between maternal infections and preeclampsia: a systematic review of epidemiologic studies. Matern Child Health J. 2008;12(2):223–42.CrossRefPubMed
20.
21.
Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL, Poole C, Smith JS. Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer. 2013;133(6):1271–85.CrossRefPubMed
22.
Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;31:14–9.CrossRef
23.
24.
Armbruster-Moraes E, Ioshimoto LM, Leao E, Zugaib M. Detection of human papillomavirus deoxyribonucleic acid sequences in amniotic fluid during different periods of pregnancy. Am J Obstet Gynecol. 1993;169(4):1074.CrossRefPubMed
25.
Weyn C, Thomas D, Jani J, Guizani M, Donner C, Van Rysselberge M, Hans C, Bossens M, Englert Y, Fontaine V. Evidence of human papillomavirus in the placenta. J Infect Dis. 2011;203(3):341–3.CrossRefPubMedPubMedCentral
26.
Sarkola ME, Grenman SE, Rintala MA, Syrjanen KJ, Syrjanen SM. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand. 2008;87(11):1181–8.CrossRefPubMed
27.
Lee SM, Park JS, Norwitz ER, Koo JN, Oh IH, Park JW, Kim SM, Kim YH, Park CW, Song YS. Risk of vertical transmission of human papillomavirus throughout pregnancy: a prospective study. PLoS One. 2013;8(6):e66368.CrossRefPubMedPubMedCentral
28.
Boulenouar S, Weyn C, Van Noppen M, Moussa Ali M, Favre M, Delvenne PO, Bex F, Noel A, Englert Y, Fontaine V. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells. Carcinogenesis. 2010;31(3):473–80.CrossRefPubMed
29.
Gomez LM, Ma Y, Ho C, McGrath CM, Nelson DB, Parry S. Placental infection with human papillomavirus is associated with spontaneous preterm delivery. Hum Reprod. 2008;23(3):709–15.CrossRefPubMed
30.
You H, Liu Y, Agrawal N, Prasad CK, Edwards JL, Osborne AF, Korourian S, Lowery CL, Hermonat PL. Multiple human papillomavirus types replicate in 3A trophoblasts. Placenta. 2008;29(1):30–8.CrossRefPubMed
31.
Hong LJ, Oshiro BT, Chan PJ. HPV-16 exposed mouse embryos: a potential model for pregnancy wastage. Arch Gynecol Obstet. 2013;287(6):1093–7.CrossRefPubMed
32.
Henneberg AA, Patton WC, Jacobson JD, Chan PJ. Human papilloma virus DNA exposure and embryo survival is stage-specific. J Assist Reprod Genet. 2006;23(6):255–9.CrossRefPubMedPubMedCentral
33.
34.
Kwon JY, Romero R, Mor G. New insights into the relationship between viral infection and pregnancy complications. Am J Reprod Immunol. 2014;71(5):387–90.CrossRefPubMed
35.
Hermonat PL, Han L, Wendel PJ, Quirk JG, Stern S, Lowery CL, Rechtin TM. Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. Virus Genes. 1997;14(1):13–7.CrossRefPubMed
36.
McDonnold M, Dunn H, Hester A, Pacheco LD, Hankins GD, Saade GR, Costantine MM. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol. 2014;210(2):138. e131-135.CrossRefPubMed
37.
Cho G, Min KJ, Hong HR, Kim S, Hong JH, Lee JK, Oh MJ, Kim H. High-risk human papillomavirus infection is associated with premature rupture of membranes. BMC Pregnancy Childbirth. 2013;13:173.CrossRefPubMedPubMedCentral
38.
Zuo Z, Goel S, Carter JE. Association of cervical cytology and HPV DNA status during pregnancy with placental abnormalities and preterm birth. Am J Clin Pathol. 2011;136(2):260–5.CrossRefPubMed
39.
Hong JN, Berggren EK, Campbell SL, Smith JS, Rahangdale L. Abnormal cervical cancer screening in pregnancy and preterm delivery. Paediatr Perinat Epidemiol. 2014;28(4):297–301.CrossRefPubMed
40.
Conde-Ferraez L, Chan May Ade A, Carrillo-Martinez JR, Ayora-Talavera G, Gonzalez-Losa Mdel R. Human papillomavirus infection and spontaneous abortion: a case-control study performed in Mexico. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):468–73.CrossRefPubMed
41.
Skoczynski M, Gozdzicka-Jozefiak A, Kwasniewska A. Prevalence of human papillomavirus in spontaneously aborted products of conception. Acta Obstet Gynecol Scand. 2011;90(12):1402–5.CrossRefPubMed
42.
Subramaniam A, Lees BF, Becker DA, Tang Y, Khan MJ, Edwards RK. Evaluation of human papillomavirus as a risk factor for preterm birth or pregnancy-related hypertension. Obstet Gynecol. 2016;127(2):233–40.CrossRefPubMed
43.
Ticconi C, Pietropolli A, Fabbri G, Capogna MV, Perno CF, Piccione E. Recurrent miscarriage and cervical human papillomavirus infection. Am J Reprod Immunol. 2013;70(5):343–6.PubMed
44.
Slatter TL, Hung NG, Clow WM, Royds JA, Devenish CJ, Hung NA. A clinicopathological study of episomal papillomavirus infection of the human placenta and pregnancy complications. Mod Pathol. 2015;28(10):1369–82.CrossRefPubMed
45.
Higgins JPT, Green S. (editors): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration; 2011. Available from www.​handbook.​cochrane.​org
46.
Bonde U, Joergensen JS, Mogensen O, Lamont RF. The potential role of HPV vaccination in the prevention of infectious complications of pregnancy. Expert Rev Vaccines. 2014;13(11):1307–16.CrossRefPubMed
47.
Huang QT, Zhong M, Gao YF, Huang LP, Huang Q, Wang W, Wang ZJ, Yu YH. Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth. J Clin Virol. 2014;61(3):321–8.CrossRefPubMed
48.
Yang R, Wang Y, Qiao J, Liu P, Geng L, Guo YL. Does human papillomavirus infection do harm to in-vitro fertilization outcomes and subsequent pregnancy outcomes? Chin Med J. 2013;126(4):683–7.PubMed
49.
Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5:F123–38.CrossRefPubMedPubMedCentral
50.
Sjoborg KD, Eskild A. Vaccination against human papillomavirus—an impact on preterm delivery? Estimations based on literature review. Acta Obstet Gynecol Scand. 2009;88(3):255–60.CrossRefPubMed
51.
Soergel P, Makowski L, Schippert C, Staboulidou I, Hille U, Hillemanns P. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccin Immunother. 2012;8(2):243–51.CrossRefPubMed
52.
Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144(3):449–68.CrossRefPubMed
53.
Berenson AB, Patel PR, Barrett AD. Is administration of the HPV vaccine during pregnancy feasible in the future? Expert Rev Vaccines. 2014;13(2):213–9.CrossRefPubMed
54.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.CrossRefPubMedPubMedCentral
55.
56.
ACOG. The American College of Obstetricians and Gynecologists ​Practice Bulletin No 150: Early pregnancy loss. Obstetrics and gynecology. 2015;125(5):1258-67.
57.
ACOG. The American College of Obstetricians and Gynecologists Practice Bulletin No. 159 Summary: management of preterm labor. Obstetrics Gynecology. 2016;127(1):190–1.
58.
Gibson CS, Goldwater PN, MacLennan AH, Haan EA, Priest K, Dekker GA. Fetal exposure to herpesviruses may be associated with pregnancy-induced hypertensive disorders and preterm birth in a Caucasian population. BJOG. 2008;115(4):492–500.CrossRefPubMed
59.
Kramer MS. The epidemiology of adverse pregnancy outcomes: an overview. J Nutr. 2003;133(5 Suppl 2):1592S–6S.PubMed
60.
Auger N, Le TU, Park AL, Luo ZC. Association between maternal comorbidity and preterm birth by severity and clinical subtype: retrospective cohort study. BMC Pregnancy Childbirth. 2011;11:67.CrossRefPubMedPubMedCentral
61.
Ananth CV, Vintzileos AM. Epidemiology of preterm birth and its clinical subtypes. J Maternal-Fetal Neonatal Med. 2006;19(12):773–82.CrossRef
62.
63.
ACOG. ACOG Practice Bulletin No. 102: management of stillbirth. Obstetrics Gynecol. 2009;113(3):748–61.CrossRef
64.
World Health Organization. International statistical classification of diseases and related health problems, tenth revision, version 2015. Geneva: World Health Organization; 2015.
65.
ACOG. Practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstetrics Gynecol. 2002;99(1):159–67.
66.
ACOG. Practice Bulletin No. 160: premature rupture of membranes. Obstetrics Gynecol. 2016;127(1):e39-51.
67.
Lausman A, Kingdom J, Maternal Fetal Medicine C, Gagnon R, Basso M, Bos H, Crane J, Davies G, Delisle MF, Hudon L, et al. Intrauterine growth restriction: screening, diagnosis, and management. J Obstet Gynaecol Can. 2013;35(8):741–57.CrossRefPubMed
68.
69.
70.
Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG: Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract. 2012, 18(1):12-18.
71.
Thomas BH, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs. 2004;1(3):176–84.CrossRefPubMed
72.
73.
Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med. 1997;127(7):531–7.CrossRefPubMed
74.
Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M. Guidance on the conduct of narrative synthesis in systematic reviews. Lancaster: ESRC Research Methods Programme; 2006.
75.
Centre for Reviews and Dissemination. Guidance for undertaking reviews in health care. UK: CRD, University of York; 2009.
76.
Borenstein MH, Hedges LV, Higgins JPT, Rothstein HR. Random-effects model. In: Introduction to Meta-Analysis. United Kingdom: John Wiley and Sons, Ltd; 2009: 70-72.
77.
78.
Borenstein MH, Hedges LV, Higgins JPT, Rothstein HR. Publication bias. In: Introduction to meta-Analysis. United Kingdom: John Wiley and Sons, Ltd; 2009. p. 277–92.
79.
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.CrossRefPubMed
80.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.CrossRefPubMed
81.
Young MM, Stevens A, Porath-Waller A, Pirie T, Garritty C, Skidmore B, Turner L, Arratoon C, Haley N, Leslie K, et al. Effectiveness of brief interventions as part of the screening, brief intervention and referral to treatment (SBIRT) model for reducing the non-medical use of psychoactive substances: a systematic review protocol. Syst Rev. 2012;1:22.CrossRefPubMedPubMedCentral
82.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12.CrossRefPubMed
83.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34.CrossRefPubMed
Metadata
Title
The association between adverse pregnancy outcomes and maternal human papillomavirus infection: a systematic review protocol
Authors
Joseph Niyibizi
Nadège Zanré
Marie-Hélène Mayrand
Helen Trottier
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Systematic Reviews / Issue 1/2017
Electronic ISSN: 2046-4053
DOI
https://doi.org/10.1186/s13643-017-0443-5

Other articles of this Issue 1/2017

Systematic Reviews 1/2017 Go to the issue

Research

Relationship between family caregiver burden and physical frailty in older adults without dementia: a systematic review

Protocol

Protocol for a realist review of workplace learning in postgraduate medical education and training

Letter

SEED: a tool for disseminating systematic review data into Wikipedia

Protocol

Interventions to control myopia progression in children: protocol for an overview of systematic reviews and meta-analyses

Protocol

Family resilience and adaptive coping in children with juvenile idiopathic arthritis: protocol for a systematic review

Protocol

Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review